Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-12-15
2000-05-23
Richter, Johann
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
546122, A01N 4340, C07D47104
Patent
active
06066648&
ABSTRACT:
The present invention relates to compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the vitronectin receptors .alpha..nu..beta.3 and/or .alpha..nu..beta.5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, viral disease, and tumor growth.
REFERENCES:
patent: 5455243 (1995-10-01), Duggan et al.
patent: 5668159 (1997-09-01), Jin et al.
Duggan Mark E.
Meissner Robert S.
Perkins James J.
Durette Philippe L.
Keating Dominic
Merck & Co. , Inc.
Richter Johann
Sabatelli Anthony D.
LandOfFree
Integrin receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Integrin receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Integrin receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1837313